165 results about "Receptor antibody" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.

The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of use for delivery of cargo to brain tissue. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

The invention discloses a preparation method of a sandwich structure immunosensor based on surface enhanced Raman scattering and application of the sandwich structure immunosensor to detection of an anti-phospholipase A2 receptor antibody, and is characterized by comprising the following steps: sputtering silver ions on a cotton swab / ZIF-67 prepared by an in-situ growth method by adopting an ion sputtering method to obtain a cotton swab / ZIF-67 / Ag NPs composite material; the preparation method comprises the following steps: preparing an antigen solution, then adding the antigen solution into the antigen solution to obtain an immune substrate, adding a methylene blue aqueous solution into a silver nanoparticle solution for reaction, then connecting an anti-human PLA2R IgG antibody to obtain an immune probe, and finally dropwise adding a phosphate buffer solution containing an antibody to be detected onto the immune substrate, and dropwise adding the immune probe solution to the immune substrate adsorbed with the antibody to be detected to obtain the sandwich structure immunosensor based on surface enhanced Raman scattering. The method has the advantages of high sensitivity, good selectivity and strong stability.

Provided herein are chimeric cytokine receptors bearing a binding domain capable of binding a TGF-β ligand or a TGF-β receptor antibody. When present on chimeric antigen receptor (CAR)-bearing immune cells (CAR-T-cells), such receptors allow for increased CAR-T cell expansion, activity and persistence, constitutively and / or through engagement of a TGF-β ligand or a TGF-β receptor antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating unacceptable pain in subjects with rheumatoid arthritis. Subjects with unacceptable pain can have, e.g., refractory pain or strict refractory pain.

The present disclosure provides anti-tyrosine-protein kinase membrane receptor 1 antibody-drug conjugate structures. The antibody-drug conjugate structures include a branched linker, where two or more payloads per branched linker are attached to an antibody. In addition, the disclosure also encompasses compounds and methods for production of such conjugates. In addition, the disclosure also encompasses methods of using the conjugates.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6 / 7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6 / 7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6 / 7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

The invention provides a means for a treatment for a demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, and also for reducing the risk of relapse in the demyelinating disease, comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.

Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.

The present invention relates to a fluorescent detection kit for detecting hydroxocobalamin receptor antibodies in central nervous system vitamin B12 deficiency and its application, which can efficiently and accurately detect the presence and concentration of anti-CD320 antibodies in patient serum or cerebrospinal fluid. The kit uses a specific antibody to bind to the CD320 protein produced by cells expressing the CD320 gene, which then binds to a fluorescently labeled secondary antibody to generate a fluorescent signal, thereby diagnosing central nervous system vitamin B12 deficiency. The base sequence in this application ensures the effective expression of the CD320 gene, which is crucial for improving the sensitivity and specificity of the test.

The present disclosure provides masked anti-tyrosine-protein kinase membrane receptor antibody-drug conjugate structures. The antibody-drug conjugate structures include a branched linker, where two or more payloads per branched linker are attached to an antibody. In addition, the disclosure also encompasses compounds and methods for production of such conjugates. In addition, the disclosure also encompasses methods of using the conjugates.

The present disclosure provides methods of treating gastric cancer or esophageal cancer in a subject in need thereof by administering a therapeutically effective amount of a bispecific anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody.

Pharmaceutical compositions of anti-TSLP-R antibodies and uses thereof are provided herein. Pharmaceutical compositions can include, for example, an anti-TSLP-R antibody, or an antigen-binding fragment thereof, pharmaceutically acceptable buffers, excipients, and surfactants, or other compositions as provided herein.

The present disclosure relates to anti-CCR8 (chemokine (C-C motif) receptor 8) antibodies, antigen binding fragments and uses thereof.

Provided are an antibody or an antigen binding fragment thereof which specifically binds to the IL-4R antigen, and a preparation method, a composition and an application. The IL-4R antibody may be used for preparing a drug which treats and / or prevents inflammation or allergies, or for immunological IL-4R antigen detection.

The present invention relates to anti-chemokine-like receptor 1 antibodies and therapeutic uses thereof. The present invention provides anti-CMKLR1 compounds having agonist ability for the interaction between Resolvin E1 and CMKLR1, and their use in the treatment or prevention of diseases, particularly diseases in which inflammation regression is delayed or disrupted.

This invention relates to a novel use of IL-1β-ligand / IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1b ligand-IL-1 receptor interaction, IL-1b antibodies or IL-1 receptor antibodies, e.g. IL-1b binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1b binding compounds or IL-1 receptor binding compounds, and / or RNA compounds decreasing either IL-1b ligands or IL-1 receptor protein levels, in the treatment and / or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and / or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some cases, the antibodies are cross-reactive with one or more non-human animal uPAR polypeptides, such as non-human primate uPAR, e.g., cynomolgus monkey uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins, and conjugates of the present disclosure to treat conditions associated with uPAR expression and / or activity are also provided. In some embodiments, the condition associated with uPAR expression and / or activity is cancer. Non-limiting examples of such cancers include cancers characterized by cancer cells expressing uPAR on their surface, cancers characterized by stromal cells within the tumor microenvironment expressing uPAR on their surface, and the like.

The present disclosure relates to the use of an anti-IL6 receptor antibody for treating rheumatoid arthritis in subjects with serum concentrations of certain biomarkers.

The disclosure relates to methods and compositions for the treatment of lupus nephritis (LN) with anti-type I IFN receptor inhibitor antibody Anifrolumab. Results of clinical trials with intravenous and subcutaneous administration of Anifrolumab. Identification of markers for LN and delivery devices and pre-filled syringe for administration of Anifrolumab.

This invention provides an antibody that binds to the Frizzled receptor, particularly an antibody that binds to the Frizzled receptor 4-cysteine-rich domain, and a method for using the same. [Solution] The present invention provides an isolated antibody and immunoconjugate that specifically bind to the Frizzled receptor (FZD) 4 cysteine-rich domain (CRD), comprising a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises complementarity-determining regions CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises complementarity-determining regions CDR-L1, CDR-L2, and CDR-L3, and the amino acid sequence of the CDR comprises or consists of a sequence selected from a specific group of sequences.

Provided is a heterohybridoma-based method of generating recombinant rabbit monoclonal antibodies, recombinant anti-IL-6 receptor-alpha (IL-6Rα) antibodies generated using such methods, and immune assay methods kits employing such antibodies.

The present invention relates to methods of reducing occurrence or severity of dermatologic adverse events (DAEs) in a subject treated with an anti-epidermal growth factor receptor (EGFR) / hepatocyte growth factor receptor (c-Met) antibody and EGFR tyrosine kinase inhibitor, comprising (a) administering an antibiotic(s); (b) administering an antiseptic(s); and (c) administering a non-comedogenic moisturizer to the subject.

Provided herein are an antibody or antigen binding fragment that specifically recognizes and / or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.

Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).

The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.

To provide a new method for treating lupus nephritis (LN), which improves renal response, reduces recurrence, prevents eventual end-stage renal disease (ESRD), and reduces the need for glucocorticoids.SOLUTION: WHAT IS CLAIMED IS: 1. A method of reducing lupus nephritis (LN) disease activity in a subject in need thereof, comprising administering to the subject a type I IFN receptor (IFNAR1) inhibiting agent. Preferably, the IFNAR1 inhibitors are human monoclonal antibodies specific for IFNAR1, such as anifrolumab.SELECTED DRAWING: None

The present invention provides caninized mouse antibodies to canine IL-31 receptor alpha that have a high binding affinity for canine IL-31 receptor alpha, and that can block the binding of canine IL-31 to canine IL-31 receptor alpha. The present invention further provides the use of the antibodies for the treatment of atopic dermatitis in dogs.